Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore

BACKGROUND AND AIM: The prohibitively high cost of direct‐acting antivirals (DAA) for hepatitis C virus (HCV) infection remains a barrier to treatment access in Singapore. We aimed to evaluate whether DAA as first‐line therapy would be cost‐effective for genotype 3 (GT3) HCV patients compared with p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Yu‐Jun, Cheen, McVin HH, Hsiang, John C, Kumar, Rahul, Tan, Jessica, Teo, Eng K, Thurairajah, Prem H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586564/
https://www.ncbi.nlm.nih.gov/pubmed/31276038
http://dx.doi.org/10.1002/jgh3.12139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586564/
https://www.ncbi.nlm.nih.gov/pubmed/31276038
http://dx.doi.org/10.1002/jgh3.12139

Ejemplares similares